Affiliations: [a] University Medical Center Goettingen (UMG), Georg-August-University, Department of Psychiatry and Psychotherapy, Goettingen, Germany
| [b] German Center for Neurodegenerative Diseases (DZNE), Goettingen, Germany
| [c] iBiMED, Medical Science Department, University of Aveiro, Portugal
| [d] University Medical Center Goettingen (UMG), Georg-August-University, Clinician Scientist College, Goettingen, Germany
| [e] McLean Hospital, Harvard Medical School, Translational Neuroscience Laboratory, Belmont, MA, USA
Correspondence:
[*]
Correspondence to: Dr. Jonathan Vogelgsang, University Medical Center Goettingen, Department of Psychiatry and Psychotherapy, Von-Siebold-Str. 5, 37075 Goettingen, Germany. Tel.: +49 551 39 66610; E-mail: jonathan.vogelgsang@med.uni-goettingen.de.
Abstract: Previous studies on blood-based biomarkers for Alzheimer’s disease suggest a less invasive blood test might be a valuable screening tool for Alzheimer-specific pathology. Pre-analytical sample storage conditions seem to play an important role on amyloid-β (Aβ) stability, impacting reliability and reproducibility. This study shows that Aβ40, Aβ42, and Aβ42/40 levels significantly and early decrease during storage at room temperature in whole blood or plasma. Storing blood samples at 4°C leads to stable Aβ peptide concentrations up to 72 h. In addition, Aβ peptides can be measured in capillary blood with a stable Aβ42/40 ratio up to 72 h at 4°C.
